Valirx Plc (VALX)

Currency in GBP
0.1600
-0.0050(-3.13%)
Real-time Data·
Advertisement
Trading near 52-week Low
VALX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.15000.1700
52 wk Range
0.15000.8485
Key Statistics
Bid/Ask
0.15 / 0.16
Prev. Close
0.16
Open
0.1615
Day's Range
0.15-0.17
52 wk Range
0.15-0.8485
Volume
420.66K
Average Volume (3m)
16.16M
1-Year Change
-73.3333%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VALX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Valirx Plc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Sell
Moving Averages
Strong Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
22/06/2026
EPS / Forecast
-- / --
Revenue / Forecast
31.37K / --
EPS Revisions
Last 90 days

Valirx (VALX) Income Statement & Profits

Compare VALX to Peers and Sector

Metrics to compare
VALX
Peers
Sector
Relationship
P/E Ratio
−0.6x−9.4x−0.4x
PEG Ratio
−0.01−0.220.00
Price/Book
0.4x3.9x2.6x
Price / LTM Sales
39.2x8.9x3.0x
Upside (Analyst Target)
-145.0%49.1%
Fair Value Upside
Unlock−8.8%6.3%Unlock

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells. The company also develops and commercializes oncology assets in the veterinary market. It has an agreement with University of Dundee. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
0.000.00%0.00
Other Institutional Investors
600.26M78.18%960.42K
Public Companies & Retail Investors
167.54M21.82%268.07K
Total
767.8M100.00%1.23M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Aberdeen Group Plc33.98%260,867,265417
Hargreaves Lansdown Asset Management Ltd.18.99%145,774,739233

FAQ

What Is the Valirx (London: VALX) Share Price Today?

The Valirx stock price today is 0.1600 GBP.

What Stock Exchange Does Valirx (VALX) Trade On?

Valirx is listed and trades on the London Stock Exchange.

What Is the Ticker (Stock Symbol) for Valirx?

The stock symbol (also called a 'ticker') for Valirx is "VALX."

What Is the Current Valirx Market Capitalisation?

As of today, Valirx (London: VALX) market cap is 1.2300M GBP.

What Is Valirx's (VALX) Earnings Per Share (TTM)?

The Valirx EPS is currently -0.0054 (Trailing Twelve Months).

When Is the Next Valirx Earnings Date?

Valirx's next earnings report will be released on 08/09/2026.

Is VALX a Buy or Sell From a Technical Analyst Perspective?

Based on today's Valirx moving averages and other technical indicators, the daily buy/sell signal for VALX stock is Strong Sell.

How Many Times Has Valirx Stock Split?

Valirx has split 6 times. (See the VALX stock split history page for full effective split date and price information.)

How Many Employees Does Valirx Have?

Valirx has 14 employees, based on their latest Companies House report.

What is the current trading status of Valirx (London: VALX)?

As of 06/07/2026, Valirx (VALX) is trading at a share price of 0.1600 GBP, with a previous close of 0.1600 GBP. The stock has fluctuated within a day range of 0.1500 GBP to 0.1700 GBP, while its 52-week range spans from 0.1500 GBP to 0.8485 GBP.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.